ArticleJournal of biological engineering2025
A novel PNIPAM-Modified polyurethane/carboxymethyl cellulose photo-thermoresponsive hydrogel loaded with gemcitabine to suppress esophageal cancer cells via VEGF-mediated angiogenic pathway inhibition.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Injectable Thermoresponsive Hydrogels for Localized Drug Delivery: Mechanisms, In Vivo Evidence and Translational Challenges.Journal of functional biomaterials · 2026Review
- Engineered chitosan/HP-β-CD hydrogel for targeted co-delivery of curcumin and berberine for the treatment of ulcerative colitis.Journal of biological engineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports the development of a thermoresponsive hydrogel composed of poly(N-isopropylacrylamide)-modified polyurethane (PNIPAM-PU) and carboxymethyl cellulose (CMC) for the controlled delivery of gemcitabine (GEM) in esophageal cancer treatment. Characterization by XRD and FTIR confirmed successful synthesis and structural integrity. The drug loading capacities were 76.2 ± 2.5% for PNIPAM-PU/CMC@GEM and 83.4 ± 3.4% for PNIPAM-PU/CMC@GEM + NIR. SEM analysis revealed pore diameters of 46.96 ± 12.94 μm (PU/CMC) and 42.96 ± 13.49 μm (PNIPAM-PU/CMC@GEM). Rheological analysis showed a sharp sol–gel transition at 37 °C. Drug release reached 25% over 24 h without NIR, increasing to 75% with NIR exposure. In vitro MTT assay showed significant cytotoxicity in KYSE-140 cells, with IC₅₀ values of 52.85 ± 2.5, 90.97 ± 3.6, 60.76 ± 2.8 and 41.59 ± 2.4 µg/mL for GEM, PU/CMC, PNIPAM-PU/CMC@GEM, and PNIPAM-PU/CMC@GEM + NIR, respectively. Biocompatibility assessment using the normal human esophageal epithelial cell line Het-1 A demonstrated increased cell viability (85%) without showing any morphological changes when treated with fabricated hydrogel formulations, confirming the non-toxic nature of the carrier system. Further, JC-1 and AO-EB staining confirmed mitochondrial depolarization and apoptosis of KYSE-140 cells after exposed to PNIPAM-PU/CMC@GEM + NIR. In vivo studies demonstrated tumor inhibition rates of 48.72%, 10.26%, 61.54%, and 74.36% for GEM, PU/CMC, PNIPAM-PU/CMC@GEM, and PNIPAM-PU/CMC@GEM + NIR, respectively, with minimal side effects. qRT-PCR and Western blot analysis showed VEGF downregulation and angiogenesis inhibition. These findings support the potential of PNIPAM-PU/CMC@GEM hydrogel as an effective localized therapy for esophageal squamous cell carcinoma (ESCC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.